Metabolism-driven Immune Escape Defines Therapeutic Vulnerability in Type I and Type II Ovarian Cancer
Anticancer Research · 2026
DOI: 10.21873/anticanres.18164 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Anticancer Research, 2026. Verfasst von Kohei Miyata und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Tumor Escape. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
- Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan yotsumoto@fukuoka-u.ac.jp.
Zitieren
APA
Miyata, K., & Yotsumoto, F. (2026). Metabolism-driven Immune Escape Defines Therapeutic Vulnerability in Type I and Type II Ovarian Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.18164
Vancouver
Miyata K, Yotsumoto F. Metabolism-driven Immune Escape Defines Therapeutic Vulnerability in Type I and Type II Ovarian Cancer. Anticancer Research. 2026. doi:10.21873/anticanres.18164
BibTeX
@article{Miyata2026,
author = {Miyata, Kohei and Yotsumoto, Fusanori},
title = {Metabolism-driven Immune Escape Defines Therapeutic Vulnerability in Type I and Type II Ovarian Cancer},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.18164}
}
EUVIMED